Risk adjusted net present value: What is the current valuation of Kissei Pharmaceutical’s Cretostimogene Grenadenorepvec?

Cretostimogene Grenadenorepvec is an oncolytic virus commercialized by Kissei Pharmaceutical, with a leading Phase III program in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer).

Source link
#Risk #adjusted #net #present #current #valuation #Kissei #Pharmaceuticals #Cretostimogene #Grenadenorepvec